1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Increase Innovative Drug Co. Ltd. has 1 pending office action. The matter is assigned to 1 distinct examiner, ZHANG SPIERING, DONGXIU, who is also the busiest examiner with 1 pending matter.
No technology area is provided, and the data records 0 distinct art units. Review should therefore center on the specific action and examiner history without assigning a technology or art unit context.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHANG SPIERING, DONGXIU | 1 | 41.2% | +65.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18995122 | FUDOSTEINE NEBULIZATION INHALATION SOLUTION COMPOSITION, DRUG ASSEMBLY, AND USE THEREOF | ZHANG SPIERING, DONGXIU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18995122 | FUDOSTEINE NEBULIZATION INHALATION SOLUTION COMPOSITION, DRUG ASSEMBLY, AND USE THEREOF | ZHANG SPIERING, DONGXIU | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18995122 | FUDOSTEINE NEBULIZATION INHALATION SOLUTION COMPOSITION, DRUG ASSEMBLY, AND USE THEREOF | ZHANG SPIERING, DONGXIU | — | §103§112 | Non-Final OA | — | Pending | Jan 15, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Increase Innovative Drug Co. Ltd. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Dongxiu Zhang Spiering has the most, with 1 of Beijing Increase Innovative Drug Co. Ltd.'s pending office actions.
